| METHODS
There are 81 FDA-approved medications for acne vulgaris, 5 isotretinoin, and 76 non-isotretinoin. The financial costs of these drugs include drug price, laboratory costs, and clinic visit charges. Medication cost was referenced by the National Average Drug Acquisition Cost (NADAC) weekly comparison data, with our data obtained on November 30, 2016 (NADAC, 2016 . The NADAC data are compiled through U.S. Centers for Medicare and Medicaid Services (CMS)-sponsored surveys of retail community pharmacy prices and includes ingredient costs (Center for Medicare & Medicaid Services, 2013) . For topical and oral acne therapies, we used the FDA-approved dosing for each medication. For isotretinoin, we looked at ranges of therapies for different weights (45, 70, and 90 kg) at the highest treatment endpoint (150 mg/kg total body weight).
Laboratory test prices were standard fees based on the 2017 CMS clinical diagnostic laboratory fee (Centers for Medicare & Medicaid Services, 2017), and their frequency was based on the most recent guidelines (Zaenglein et al., 2016) . Billing codes and frequency of follow-ups were also based on our practice norms.
Total cost calculations were standardized to 7-months of treatment as this is the endpoint when patients treated with isotretinoin will have achieved the upper end of their weight-based cumulative dose (150 mg/kg total body weight; Layton, 2009 ).
| RESULTS
The range of isotretinoin drug costs alone was $1,321 (45 kg person taking Claravis, Myorisan, or Zenatane) to $11,680 (90 kg person taking Absorica). The total cost ranges, including drug costs as well as associated laboratory costs and office visit charges, are higher (Table 1) .
Over a 7-month treatment period, the range of total costs for isotretinoin was $2,629 and $2,774 (45 kg male and female taking Claravis, Myorisan, and Zenatane) to $12,989 and $13,133 (90 kg male and female taking Absorica).
The non-isotretinoin topical and oral medications were categorized by class and their cost calculations (Table 2) . Total cost ranges (lowest and highest) over a 7-month treatment period were:
• Oral antibiotics The most expensive medications were in the classes of topical antibiotics (high end was $4,604 for Dapsone 5% 90 g gel tube), topical retinoids (high end was $7,528 for Tazarotene 0.1% gel 100 g tube), and topical antibiotic and retinoid combination medications (high end was $5,017 for Clindamycin-Tretinoin 1.2%-0.025% 60 g gel).
Figure 1 summarizes the range of costs for all surveyed drugs in each class across a 2-year treatment period with a median value provided to allow for comparison. The median values for isotretinoin were approximated using the mean values of the high and low total costs for each drug for each gender to represent the cost of a typical male and female patient of average weight at an average dose. Importantly, the large variation in the cost of isotretinoin is because of the very high cost of one brand of isotretinoin (Absorica).
| DISCUSSION
Cost is an important consideration in the treatment of acne vulgaris.
The average total cost of a single episode of acne was $689 (Lee & Cooper, 1991) , a reoccurring expense that can create a significant financial burden to both the patient and the overall health care system. In a market filled with uncertainty and ever-increasing out-ofpocket costs, the financial impact of treatment is important for the clinician to consider.
The present study calculates cost efficacy among all acne vulgaris treatments approved by the FDA. Spironolactone 25 mg tablet was the cheapest treatment option and one brand of isotretinoin (Absorica), the most expensive. However, the data are not as clear when considering the potential for isotretinoin to produce durable remission. Remission rates for isotretinoin vary based on cumulative dosage, with studies on dosages between 0.5 and 1.0 mg/kg/day dosing finding sustained improvement requiring no further treatment in the 50-80% range (Del Rosso, 2012; Haryati & Jacinto, 2005; Layton, 2009; Stainforth, Layton, Taylor, & Cunliffe, 1993) . Thus, the cost savings difference between isotretinoin and combination medications in moderate to severe acne, particularly when long-term outcome is considered, strongly favors isotretinoin in the United States; this is supported by similar results in other health systems as well (Cunliffe, Gray, & MacDonald-Hull, 1991; Layton, 2009; Lee & Cooper, 1991; Newton, 1997; Wessels, Anderson, & Kropman, 1999; Wishart & Villiger, 1991) . For example, the use of one unit of Adapalene and benzoyl peroxide 0.1-2.5% 45 g gel pump (Epiduo) monthly over 1 year far surpasses the cost of one treatment course with isotretinoin (Clavaris). Both represent the lowest cost option in their therapeutic class according to our data. Similarly, although certain acne medications may be preferable in terms of cost in the short-term, their cumulative total cost after prolonged therapy will certainly exceed that of one course of isotretinoin (Figure 1) . The prevalence and costs of combination therapies (i.e., a topical and oral medication) make the cost advantage of isotretinoin even more meaningful. This represents a potential opportunity for cost savings in a population of patients The values in Column 3 reflect the low (45 kg person) and high range (90 kg person) drug costs from Table 1 We caution that the present study ignores many other factors that may preclude consideration of cost on treatment options. The true cost of a medication to a patient is difficult to calculate given differences in regional pricing, availability, personal burden and opportunity costs in leaving work for (Mori et al., 2016) clinician practice patterns, and widely variable levels of laboratory testing (Shinkai, McMichael, & Linos, 2016) . Moreover, insurance plans, promotional incentives, and rebates all play a role in patient costs. Indeed, drug costs themselves change over time. These factors are not considered in this article as it would be difficult to fully represent them in a meaningful way. This article also does not consider the impact of potential adverse effects and comorbidities on drug costs. Side effects of isotretinoin generally mimic hypervitaminosis A and involve the The medication cost per treatment period (Column 7) assumes 7 months of therapy. We also factored in the office visit cost assuming 7 months of therapy, which is typically twice for oral medications and once for topical medications. There are no associated routine laboratory tests for any of these therapies. The two columns at the far right of the table show the total medication costs for the 7-month treatment period and the rank of the medication, with lower numbers equating to lower cost. mucocutaneous, musculoskeletal, and ophthalmic systems. Other debated side effects include inflammatory bowel disease, depression/ anxiety/mood changes, cardiovascular risk factors, bone mineralization, concerns regarding scarring, and Staphylococcus aureus colonization (Zaenglein et al., 2016) .
Limitations aside, the present study analyzes cost efficacy among FDA-approved treatments for acne. Importantly, this analysis is not meant to dictate treatments based solely on costs; rather, our analysis provides cost efficacy data that can be considered as part of the many factors that ultimately lead to treatment selection. Given the quickly changing health care landscape in the United States, we feel that this data require long-term follow-up as drug prices change over time.
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https://orcid.org/0000-0002-3262-9386 FIGURE 1 Drug costs by class as a range from the least expensive drug in the class to the most expensive across a 2-year treatment period. There is a median value provided to allow for comparison. The median values for isotretinoin were calculated from the mean of the high and low total costs for each drug for each gender, shown in Table 1 , to represent the cost of a typical male and female patient of average weight at an average dose. Initially the high and low costs for each isotretinoin were calculated. The high cost represents the most expensive drug iteration of the drug (90 kg patient), and the low cost represents the least expensive (45 kg patient). The mean of these two values was used to calculate the median across all versions of isotretinoin for each gender
